Key result
Vitamin B5 and derivatives show potential therapeutic value for CoA-deficient cardiomyopathies and heart failure.
Answers are grounded in this paper and cite their sources.
Coenzyme A (CoA) is an essential cofactor required for over a hundred metabolic reactions in the human body. This cofactor is synthesized de novo in our cells from vitamin B5, also known as pantothenic acid, a water-soluble vitamin abundantly present in vegetables and animal-based foods. Neurodegenerative disorders, cancer, and infectious diseases have been linked to defects in de novo CoA biosynthesis or reduced levels of this coenzyme. There is now accumulating evidence that CoA limitation is a critical pathomechanism in cardiac dysfunction too. In the current review, we will summarize our current knowledge on CoA and heart failure, with emphasis on two primary cardiomyopathies, phosphopantothenoylcysteine synthetase and phosphopantothenoylcysteine decarboxylase deficiency disorders biochemically characterized by a decreased level of CoA in patients' samples. Hence, we will discuss the potential benefits of CoA restoration in these diseases and, more generally, in heart failure, by vitamin B5 and its derivatives pantethine and 4'-phosphopantetheine.
No takes yet. Share an insight, caveat, or question.
Wedman et al. (2024) conducted a review in Heart failure and primary cardiomyopathies (phosphopantothenoylcysteine synthetase and phosphopantothenoylcysteine decarboxylase deficiency disorders). Vitamin B5 (pantothenic acid) and derivatives (pantethine and 4'-phosphopantetheine) was evaluated. Vitamin B5 and its derivatives pantethine and 4'-phosphopantetheine may provide potential benefits by restoring coenzyme A levels in primary CoA-deficient cardiomyopathies and heart failure.
Synapse has enriched 10 related papers. Consider them for comparative context: